vs

Side-by-side financial comparison of CareDx, Inc. (CDNA) and Ribbon Communications Inc. (RBBN). Click either name above to swap in a different company.

Ribbon Communications Inc. is the larger business by last-quarter revenue ($162.6M vs $117.7M, roughly 1.4× CareDx, Inc.). Ribbon Communications Inc. runs the higher net margin — 54.8% vs 2.4%, a 52.4% gap on every dollar of revenue. On growth, CareDx, Inc. posted the faster year-over-year revenue change (39.0% vs -10.3%). Over the past eight quarters, CareDx, Inc.'s revenue compounded faster (12.9% CAGR vs -8.1%).

CareDx, Inc. is a leading precision medicine company dedicated to organ transplant patient care. It develops and commercializes diagnostic tests for rejection surveillance, digital health management tools, and supportive clinical services, catering to transplant clinicians, patients, and healthcare systems across North America and European core markets.

Ribbon Communications Inc. is a public company that makes software, IP and optical networking solutions for service providers, enterprises and critical infrastructure sectors. The company was formed in 2017, following the merger of Genband and Sonus Networks and is headquartered in Plano, Texas.

CDNA vs RBBN — Head-to-Head

Bigger by revenue
RBBN
RBBN
1.4× larger
RBBN
$162.6M
$117.7M
CDNA
Growing faster (revenue YoY)
CDNA
CDNA
+49.3% gap
CDNA
39.0%
-10.3%
RBBN
Higher net margin
RBBN
RBBN
52.4% more per $
RBBN
54.8%
2.4%
CDNA
Faster 2-yr revenue CAGR
CDNA
CDNA
Annualised
CDNA
12.9%
-8.1%
RBBN

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
CDNA
CDNA
RBBN
RBBN
Revenue
$117.7M
$162.6M
Net Profit
$2.8M
$89.1M
Gross Margin
42.9%
Operating Margin
1.0%
37.6%
Net Margin
2.4%
54.8%
Revenue YoY
39.0%
-10.3%
Net Profit YoY
EPS (diluted)
$0.05
$0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CDNA
CDNA
RBBN
RBBN
Q1 26
$117.7M
$162.6M
Q4 25
$108.4M
$227.3M
Q3 25
$100.1M
$215.4M
Q2 25
$86.7M
$220.6M
Q1 25
$84.7M
$181.3M
Q4 24
$86.6M
$251.4M
Q3 24
$82.9M
$210.2M
Q2 24
$92.3M
$192.6M
Net Profit
CDNA
CDNA
RBBN
RBBN
Q1 26
$2.8M
$89.1M
Q4 25
$-4.1M
Q3 25
$1.7M
$-12.1M
Q2 25
$-8.6M
$-11.1M
Q1 25
$-10.4M
$-26.2M
Q4 24
$87.7M
Q3 24
$-10.6M
$-13.4M
Q2 24
$-4.6M
$-16.8M
Gross Margin
CDNA
CDNA
RBBN
RBBN
Q1 26
42.9%
Q4 25
53.3%
Q3 25
50.1%
Q2 25
49.6%
Q1 25
45.4%
Q4 24
55.7%
Q3 24
52.1%
Q2 24
50.8%
Operating Margin
CDNA
CDNA
RBBN
RBBN
Q1 26
1.0%
37.6%
Q4 25
-5.6%
4.1%
Q3 25
-0.2%
1.3%
Q2 25
-12.8%
1.9%
Q1 25
-15.8%
-10.8%
Q4 24
97.5%
13.2%
Q3 24
-16.6%
-0.4%
Q2 24
-7.9%
-1.0%
Net Margin
CDNA
CDNA
RBBN
RBBN
Q1 26
2.4%
54.8%
Q4 25
-3.8%
Q3 25
1.7%
-5.6%
Q2 25
-9.9%
-5.0%
Q1 25
-12.2%
-14.5%
Q4 24
101.3%
Q3 24
-12.8%
-6.4%
Q2 24
-5.0%
-8.7%
EPS (diluted)
CDNA
CDNA
RBBN
RBBN
Q1 26
$0.05
$0.50
Q4 25
$-0.08
$0.50
Q3 25
$0.03
$-0.07
Q2 25
$-0.16
$-0.06
Q1 25
$-0.19
$-0.15
Q4 24
$1.60
$0.05
Q3 24
$-0.20
$-0.08
Q2 24
$-0.09
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CDNA
CDNA
RBBN
RBBN
Cash + ST InvestmentsLiquidity on hand
$77.9M
$67.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$419.1M
Total Assets
$411.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CDNA
CDNA
RBBN
RBBN
Q1 26
$77.9M
$67.6M
Q4 25
$177.2M
$96.4M
Q3 25
$194.2M
$74.8M
Q2 25
$186.3M
$60.5M
Q1 25
$230.9M
$71.2M
Q4 24
$260.7M
$87.8M
Q3 24
$240.9M
$37.2M
Q2 24
$228.9M
$64.6M
Total Debt
CDNA
CDNA
RBBN
RBBN
Q1 26
Q4 25
$342.1M
Q3 25
$344.3M
Q2 25
$346.5M
Q1 25
$347.4M
Q4 24
$348.3M
Q3 24
$0
$349.1M
Q2 24
$0
$350.0M
Stockholders' Equity
CDNA
CDNA
RBBN
RBBN
Q1 26
$419.1M
Q4 25
$303.1M
$449.0M
Q3 25
$311.1M
$360.1M
Q2 25
$327.4M
$370.4M
Q1 25
$379.3M
$381.8M
Q4 24
$378.4M
$404.6M
Q3 24
$273.2M
$395.5M
Q2 24
$264.7M
$405.0M
Total Assets
CDNA
CDNA
RBBN
RBBN
Q1 26
$411.1M
Q4 25
$413.2M
$1.2B
Q3 25
$432.3M
$1.1B
Q2 25
$444.3M
$1.1B
Q1 25
$489.6M
$1.1B
Q4 24
$491.1M
$1.2B
Q3 24
$477.0M
$1.1B
Q2 24
$466.8M
$1.1B
Debt / Equity
CDNA
CDNA
RBBN
RBBN
Q1 26
Q4 25
0.76×
Q3 25
0.96×
Q2 25
0.94×
Q1 25
0.91×
Q4 24
0.86×
Q3 24
0.00×
0.88×
Q2 24
0.00×
0.86×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CDNA
CDNA
RBBN
RBBN
Operating Cash FlowLast quarter
$4.3M
Free Cash FlowOCF − Capex
$514.0K
FCF MarginFCF / Revenue
0.4%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
1.54×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CDNA
CDNA
RBBN
RBBN
Q1 26
$4.3M
Q4 25
$21.4M
$29.2M
Q3 25
$37.4M
$26.5M
Q2 25
$9.9M
$-795.0K
Q1 25
$-26.6M
$-3.5M
Q4 24
$21.9M
$61.8M
Q3 24
$12.5M
$-14.8M
Q2 24
$18.9M
$-9.8M
Free Cash Flow
CDNA
CDNA
RBBN
RBBN
Q1 26
$514.0K
Q4 25
$27.3M
Q3 25
$21.0M
Q2 25
$-6.5M
Q1 25
$-15.7M
Q4 24
$53.8M
Q3 24
$-23.7M
Q2 24
$-12.9M
FCF Margin
CDNA
CDNA
RBBN
RBBN
Q1 26
0.4%
Q4 25
12.0%
Q3 25
9.7%
Q2 25
-2.9%
Q1 25
-8.7%
Q4 24
21.4%
Q3 24
-11.3%
Q2 24
-6.7%
Capex Intensity
CDNA
CDNA
RBBN
RBBN
Q1 26
Q4 25
0.9%
Q3 25
2.6%
Q2 25
2.6%
Q1 25
6.7%
Q4 24
3.2%
Q3 24
4.2%
Q2 24
1.6%
Cash Conversion
CDNA
CDNA
RBBN
RBBN
Q1 26
1.54×
Q4 25
Q3 25
22.30×
Q2 25
Q1 25
Q4 24
0.25×
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CDNA
CDNA

Financial Results Total$85.0M72%
Patient and digital solutions revenue$16.0M14%
Product revenue$10.3M9%
Other$6.4M5%

RBBN
RBBN

Service$94.5M58%
Product$68.1M42%

Related Comparisons